FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360984895> ?p ?o ?g. }

• W4360984895 endingPage "2541" @default.
• W4360984895 startingPage "2529" @default.
• W4360984895 abstract "Drug metabolism might be altered in patients with type 2 diabetes. We aimed to evaluate if initiation of glucose-lowering drugs impacts warfarin efficacy and drug metabolism.First, we conducted a register-based self-controlled cohort study on Danish and Scottish warfarin users. Warfarin efficacy (international normalized ratio [INR]) was compared before and after initiation of glucose-lowering drugs. Second, we conducted a clinical pharmacokinetic trial comprising treatment-naïve type 2 diabetes patients. Patients ingested probe drugs for drug-metabolizing enzymes (the Basel Cocktail) before initiating glucose-lowering treatment, and after 3 and 12 weeks of treatment. Drug metabolism, glycaemic control, and inflammation were assessed on each visit.In the Danish and Scottish cohorts (n = 982 and n = 44, respectively), initiating glucose-lowering drugs reduced warfarin efficacy. INR decreased from 2.47 to 2.21 in the Danish cohort (mean difference -0.26; 95% CI -0.35; -0.17) and from 2.33 to 2.13 in the Scottish cohort (-0.21; 95% CI -0.52; 0.11) after initiation of glucose-lowering treatment. This impact on INR was more pronounced among individuals with stronger effects of glucose-lowering treatment. In the clinical pharmacokinetic trial (n = 10), initiating metformin did not affect drug metabolism after 3 weeks (geometric mean ratio of CYP3A metabolic ratio: 1.12 [95% CI: 0.95; 1.32]) or 12 weeks of metformin treatment. Glycaemic control improved during treatment, while inflammation remained low and unchanged during treatment.In conclusion, initiation of glucose-lowering drugs among chronic warfarin users seems associated with a reduction in INR, particularly among individuals with a large decrease in HbA1c . This effect seems unrelated to CYP enzyme activity and warfarin drug metabolism." @default.
• W4360984895 created "2023-03-30" @default.
• W4360984895 creator A5001559337 @default.
• W4360984895 creator A5005287400 @default.
• W4360984895 creator A5005931904 @default.
• W4360984895 creator A5011631607 @default.
• W4360984895 creator A5023434070 @default.
• W4360984895 creator A5035578447 @default.
• W4360984895 creator A5039949303 @default.
• W4360984895 creator A5048581391 @default.
• W4360984895 creator A5049097258 @default.
• W4360984895 creator A5056150399 @default.
• W4360984895 creator A5059577837 @default.
• W4360984895 creator A5072859924 @default.
• W4360984895 creator A5073074221 @default.
• W4360984895 creator A5082891416 @default.
• W4360984895 creator A5084618805 @default.
• W4360984895 date "2023-04-14" @default.
• W4360984895 modified "2023-09-25" @default.
• W4360984895 title "Initiation of glucose‐lowering drugs reduces the anticoagulant effect of warfarin—But not through altered drug metabolism in patients with type 2 diabetes" @default.
• W4360984895 cites W1533842935 @default.
• W4360984895 cites W1552051186 @default.
• W4360984895 cites W2063559426 @default.
• W4360984895 cites W2150367899 @default.
• W4360984895 cites W2159756891 @default.
• W4360984895 cites W2530717584 @default.
• W4360984895 cites W2541013163 @default.
• W4360984895 cites W2606948040 @default.
• W4360984895 cites W2765589989 @default.
• W4360984895 cites W2791844482 @default.
• W4360984895 cites W2944956458 @default.
• W4360984895 cites W3201244536 @default.
• W4360984895 cites W3202635655 @default.
• W4360984895 cites W4280546967 @default.
• W4360984895 cites W4291994076 @default.
• W4360984895 cites W4293493783 @default.
• W4360984895 doi "https://doi.org/10.1111/bcp.15725" @default.
• W4360984895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36967527" @default.
• W4360984895 hasPublicationYear "2023" @default.
• W4360984895 type Work @default.
• W4360984895 citedByCount "0" @default.
• W4360984895 crossrefType "journal-article" @default.
• W4360984895 hasAuthorship W4360984895A5001559337 @default.
• W4360984895 hasAuthorship W4360984895A5005287400 @default.
• W4360984895 hasAuthorship W4360984895A5005931904 @default.
• W4360984895 hasAuthorship W4360984895A5011631607 @default.
• W4360984895 hasAuthorship W4360984895A5023434070 @default.
• W4360984895 hasAuthorship W4360984895A5035578447 @default.
• W4360984895 hasAuthorship W4360984895A5039949303 @default.
• W4360984895 hasAuthorship W4360984895A5048581391 @default.
• W4360984895 hasAuthorship W4360984895A5049097258 @default.
• W4360984895 hasAuthorship W4360984895A5056150399 @default.
• W4360984895 hasAuthorship W4360984895A5059577837 @default.
• W4360984895 hasAuthorship W4360984895A5072859924 @default.
• W4360984895 hasAuthorship W4360984895A5073074221 @default.
• W4360984895 hasAuthorship W4360984895A5082891416 @default.
• W4360984895 hasAuthorship W4360984895A5084618805 @default.
• W4360984895 hasBestOaLocation W43609848951 @default.
• W4360984895 hasConcept C112705442 @default.
• W4360984895 hasConcept C126322002 @default.
• W4360984895 hasConcept C134018914 @default.
• W4360984895 hasConcept C17093226 @default.
• W4360984895 hasConcept C2776301958 @default.
• W4360984895 hasConcept C2777180221 @default.
• W4360984895 hasConcept C2779161974 @default.
• W4360984895 hasConcept C2779306644 @default.
• W4360984895 hasConcept C2780035454 @default.
• W4360984895 hasConcept C2780323712 @default.
• W4360984895 hasConcept C555293320 @default.
• W4360984895 hasConcept C71924100 @default.
• W4360984895 hasConcept C72563966 @default.
• W4360984895 hasConcept C89311334 @default.
• W4360984895 hasConcept C98274493 @default.
• W4360984895 hasConceptScore W4360984895C112705442 @default.
• W4360984895 hasConceptScore W4360984895C126322002 @default.
• W4360984895 hasConceptScore W4360984895C134018914 @default.
• W4360984895 hasConceptScore W4360984895C17093226 @default.
• W4360984895 hasConceptScore W4360984895C2776301958 @default.
• W4360984895 hasConceptScore W4360984895C2777180221 @default.
• W4360984895 hasConceptScore W4360984895C2779161974 @default.
• W4360984895 hasConceptScore W4360984895C2779306644 @default.
• W4360984895 hasConceptScore W4360984895C2780035454 @default.
• W4360984895 hasConceptScore W4360984895C2780323712 @default.
• W4360984895 hasConceptScore W4360984895C555293320 @default.
• W4360984895 hasConceptScore W4360984895C71924100 @default.
• W4360984895 hasConceptScore W4360984895C72563966 @default.
• W4360984895 hasConceptScore W4360984895C89311334 @default.
• W4360984895 hasConceptScore W4360984895C98274493 @default.
• W4360984895 hasFunder F4320321999 @default.
• W4360984895 hasIssue "8" @default.
• W4360984895 hasLocation W43609848951 @default.
• W4360984895 hasLocation W43609848952 @default.
• W4360984895 hasLocation W43609848953 @default.
• W4360984895 hasLocation W43609848954 @default.
• W4360984895 hasLocation W43609848955 @default.
• W4360984895 hasLocation W43609848956 @default.
• W4360984895 hasLocation W43609848957 @default.
• W4360984895 hasOpenAccess W4360984895 @default.

• next